~~ Scroll left side of this blog for needed resources. Also, use our 'search by topic' tool, to find specific information.
Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.
Sunday, October 11, 2015
Vitamin D Supplements Improve Cognition in Patients With MS
BARCELONA — Patients with multiple sclerosis (MS) given vitamin D supplements showed improved cognition at 3 months, a new study shows.
The results suggest that patients with MS should get their vitamin D levels checked and, if deficient, take vitamin D supplements, said Hala Darwish, PhD, a neuroscience expert whose research at the American University of Beirut (AUB) focuses, among other things, on cognitive and inflammatory changes associated with aging.
"I'm one of those who believes that MS patients should take supplements," Dr Darwish told Medscape Medical News.
She presented results of the study here at the Congress of the European Committee for Treatment and Research in MS (ECTRIMS) 2015.
Vitamin D, which can be obtained through exposure to the sun or fortified foods, plays a role in the pathogenesis of MS, said Dr Darwish. It has been shown to improve physical function and decrease inflammation. Evidence also links vitamin D to cognitive performance in older adults.
That vitamin D affects cognition makes some biological sense, "We know there are vitamin D receptors in the brain" of both animals and humans, said Dr Darwish. "This suggests a function in cognition."
For the study, researchers recruited adult patients with MS from the AUB center who were being treated with interferon β. From blood tests, they determined that 88 patients qualified for inclusion in that they had normal serum 25-hydroxyvitamin D (25[OH]D) levels (>35 μg/mL) or were vitamin D deficient (<25 μg/mL).
Researchers collected demographic data, health history, and information on lifestyle habits. They assessed depression and anxiety using the Arabic-Hopkins Symptoms Checklist.
The low and normal vitamin D groups were similar in terms of marital status, income, and employment level. Dr Darwish noted that both groups were highly educated, with many having at least a college degree.
As for lifestyle, those with low vitamin D engaged in less physical activity than the normal vitamin D group, and they smoked more and drank more alcohol. This low vitamin D group also tended to participate in fewer leisure activities.
Disease duration did not differ between the groups, but there was a significant difference on the Expanded Disability Status Scale (EDSS), with those in the low vitamin D group having a higher mean score (1.6 vs 1.1; P = .04).
This, said Dr Darwish, might explain their differences in physical activity and being less involved in playing online video games.
Study patients were given a battery of cognitive tests, including the Montreal Cognitive Assessment; Symbol Digit Modalities Test (SDMT); Stroop test; and Brief Visuospatial Memory Test Revised (BVMT-R), immediate (10 and 30 seconds), and delayed recall (DR) (20 minutes).
All the cognitive tests were short and altogether took about 45 minutes to complete. In some cases, researchers used the Arabic version of these tests for the first time.
At baseline, the low vitamin D group scored lower on all cognitive tests except the Stroop test. The difference was significant for SDMT and BVMT-DR.
The low vitamin D group was given high doses of vitamin supplements (10,000 IU daily or 50,000 IU per week) for 3 months. The normal vitamin D group received usual care.
Read complete article here